First Amendment to Change of Control Employment Agreement



 Exhibit 10.46B 
 FIRST AMENDMENT TO 
 CHANGE OF CONTROL EMPLOYMENT AGREEMENT 
 Section 6. (a) of the Change of Control Employment Agreement by and between Kewaunee
Scientific Corporation (the “Company”), and David M. Rausch (the “Executive”), dated as of the 22nd day of March, 2005, is hereby amended as follows: 
  

	 	•	 	 Section 6. (a) (i) is hereby replaced in its entirety by the following: 


 (i) The Company shall pay to the Executive an amount equal to either: 
 A. if the Date of Termination occurs on or before the first anniversary of the Change of Control Date, the sum of the Executive’s
Annual Base Salary plus his Average Annual Bonus and the compensation for any earned but unused vacation days; or 
 B. if
the Date of Termination occurs after the first anniversary of the Change of Control Date, one-half the sum of the Executive’s Annual Base Salary plus his Average Annual Bonus and the compensation for any earned but unused vacation days.

  

	 	•	 	 Section 6. (a) (iii) is hereby replace in its entirety by the following: 


 (iii) If the Executive is a participant in the Kewaunee Scientific Corporation Executive Deferred Compensation Plan (the “Deferred
Compensation Plan”), his benefit under the Deferred Compensation Plan shall be paid in a single lump sum pursuant to Section 5.2 of the Deferred Compensation Plan regardless of whether he had elected a different form of benefit, and shall
be increased by an amount equal to the additional employer matching contributions the Executive would have received under both the Deferred Compensation Plan and the 401K Incentive Savings Plan for Salaried and Hourly Employees of Kewaunee
Scientific Corporation as if the Executive’s employment had continued until the end of the Protection Period, based on the assumption that the Executive’s compensation throughout the Protection Period would have been that required by
Section 4(b)(i) and Section 4(b)(ii), that the Executive’s would have elected to defer his compensation under both such plans at the same rate that he had elected immediately prior to the Termination Date, and that all such employer
matching contributions were fully vested at the end of the Protection Period. The provisions of this Section 6(a)(iii) shall be considered an amendment to the Deferred Compensation Plan consented to by the Executive. 
  

 1 









	 	•	 	 Section 6. (a) (iv) is hereby replaced in its entirety by the following: 


 (iv) If the Executive is a participant in the Kewaunee Scientific Corporation Group Life Insurance Benefit Plan (the “Life Insurance
Plan”), he shall also receive a payment equal to the present value of the vested death benefit, if any, to which the Executive’s beneficiaries would have been entitled under the Life Insurance Plan if the Executive’s employment had
continued until the end of the Protection Period, based on the assumption that the Executive’s compensation throughout the Protection Period would have been that required by Section 4(b)(i) and Section 4(b)(ii). Such present value
shall be determined as if the death benefit were payable at the end of the Executive’s life expectancy, determined as of the date of payment, and discounted to the date of payment, using the same mortality and interest rate assumptions used to
calculate lump sum benefits under the Retirement Plan. The provisions of this Section 6(a)(iv) shall be considered an amendment to the Life Insurance Plan consented to by the Executive, and the amount of such payment shall be in full
satisfaction of all amounts owed to the Executive’s beneficiaries under the Life Insurance Plan. 
 In all other respects, this
Agreement is reaffirmed and remains unchanged. 
 IN WITNESS WHEREOF, the Executive
has hereunto set the Executive’s hand and, pursuant to the authorization from its Board of Directors, the Company has caused this First Amendment to be executed in its name on its behalf as of this 12th day of December, 2005. 
  

			
	  
 Executive

		
	By:	 	  

		 	William A. Shumaker
		 	President, Chief Executive Officer

  

 2